| Methods |
Crossover design; each phase 28 days. 1/11 asthma patients withdrew from study. Said to be double blind (vs placebo), but some patients could distinguish the OxBr by its taste, no other details. Concurrent asthma medication: no oral steroids; inhaled steroids and oral bronchodilators. |
| Participants |
Inclusion criteria: patients had asthma ‐ reversible (>15% increase in FEV1) after beta‐agonist; stable asthma medication. Patient details: 22 participants (11 with asthma(M/F for 10: 4/6), 11 with bronchitis ‐ not separated for most outcomes); age (asthmatics) mean 59; moderate asthma; atopy not stated. |
| Interventions |
2 interventions: oxitropium bromide 200µg and placebo; both interventions t.i.d. (on rising, early pm and on retiring). |
| Outcomes |
PEF (am, early pm, retiring ‐ paired difference +SEM for am); FEV1 at 4 weeks; rescue medication (not for placebo) ‐ all these for mixed asthma/COPD; number of dropouts (asthma only). |
| Notes |
Most outcomes for athma and COPD combined; 1 author worked for Boehringer Ingelheim. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
Information not available (Cochrane Grade B) |
